{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:07:23Z","timestamp":1761156443963},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T00:00:00Z","timestamp":1518480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Reviva Pharmaceuticals, Inc"},{"name":"Pharmaceuticals"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejphar.2018.02.017","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T12:39:15Z","timestamp":1518611955000},"page":"159-166","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model"],"prefix":"10.1016","volume":"827","author":[{"given":"Laxminarayan","family":"Bhat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Hawkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Cantillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasharatha G.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema R.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles-E.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"Biernat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Salvail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.02.017_bib1","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1161\/CIRCULATIONAHA.109.927681","article-title":"Formation of plexiform lesions in experimental severe pulmonary arterial hypertension","volume":"121","author":"Abe","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejphar.2018.02.017_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/vhrm.2006.2.4.411","article-title":"Sildenafil in the treatment of pulmonary hypertension","volume":"2","author":"Barnett","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"issue":"2","key":"10.1016\/j.ejphar.2018.02.017_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2018.02.017_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2017.05.048","article-title":"RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats","volume":"810","author":"Bhat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2017.05.052","article-title":"RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia\u2013 induced pulmonary arterial hypertension in rats","volume":"810","author":"Bhat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2017.01.043","article-title":"Dopamine serotonin Stabilizer RP5063: a randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder","volume":"189","author":"Cantillon","year":"2017","journal-title":"Schizophr Res."},{"key":"10.1016\/j.ejphar.2018.02.017_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.017_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2018.02.017_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00126010","article-title":"Terguride ameliorates monocrotaline induced pulmonary hypertension in rats","volume":"37","author":"Dumitrascu","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2018.02.017_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1385\/CBB:47:1:33","article-title":"Functions of serotonin in hypoxic pulmonary vascular remodeling","volume":"47","author":"Esteve","year":"2007","journal-title":"Cell Biochem. Biophys."},{"issue":"16","key":"10.1016\/j.ejphar.2018.02.017_bib11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary Artery Hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.017_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/pr.111.005587","article-title":"The pharmacological treatment of pulmonary arterial hypertension","volume":"64","author":"Frumkin","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2018.02.017_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Gali\u00e8","year":"2004","journal-title":"Cardiovasc. Res."},{"issue":"20","key":"10.1016\/j.ejphar.2018.02.017_bib14","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"Galie","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2018.02.017_bib15","series-title":"Pulmonary Hypertension: Basic Science to Clinical Medicine.","first-page":"17","article-title":"Animal models of pulmonary hypertension","author":"Gomez-Arroyo","year":"2016"},{"issue":"11","key":"10.1016\/j.ejphar.2018.02.017_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0091270009341182","article-title":"Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study","volume":"49","author":"Gruenig","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib17","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"43","key":"10.1016\/j.ejphar.2018.02.017_bib18","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"16","author":"Humbert","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.017_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","article-title":"Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension","volume":"11","author":"Itoh","year":"2006","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome","volume":"115","author":"Lai","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2018.02.017_bib22","first-page":"438403","article-title":"5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure","author":"Janssen","year":"2015","journal-title":"Biomed Res Int."},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00210-004-1006-6","article-title":"Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs","volume":"371","author":"J\u00e4hnichen","year":"2004","journal-title":"Schmiede. Arch.\u00a0NaunynSchmiede. Arch.Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-60761-500-2_20","article-title":"The serotonin hypothesis of pulmonary hypertension revisited","volume":"661","author":"MacLean","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2018.02.017_bib25","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2018.02.017_bib26","doi-asserted-by":"crossref","first-page":"e0118655","DOI":"10.1371\/journal.pone.0118655","article-title":"Potential contribution of phenotypically modulated smooth muscle cells and related inflammation in the development of experimental obstructive pulmonary vasculopathy in rats","volume":"10","author":"Otsuki","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2018.02.017_bib28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.109.165001","article-title":"PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats","volume":"334","author":"Porvasnik","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.11-0793","article-title":"Inflammation in pulmonary arterial hypertension","volume":"141","author":"Prince","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2018.02.017_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ejphar.2018.02.017_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.autrev.2017.02.006","article-title":"Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: targeting endothelin-1 receptor to control proliferation","volume":"16","author":"R\u00e9gent","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCRESAHA.113.301129","article-title":"The Right Ventricle in Pulmonary Arterial Hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure","volume":"115","author":"Ryan","year":"2014","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2018.02.017_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cjca.2015.01.023","article-title":"Right ventricular adaptation and failure in pulmonary arterial hypertension","volume":"31","author":"Ryan","year":"2015","journal-title":"Can. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.02.017_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/689289","article-title":"Combined oral administration of L-arginine and tetrahydrobiopterin in a rat model of pulmonary arterial hypertension","volume":"7","author":"Schreiber","year":"2017","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2018.02.017_bib35","unstructured":"Shacham S., Orbach P., Marantz Y., et al., 2006. PRX-08066: A Potent 5-HT2B Receptor Antagonist with a dual disease modifying\/vasodilating mechanism for the Treatment of Pulmonary Hypertension. 2006 International PHA Conference and Scientific Sessions. Minneapolis, MN, June 23-25, 2006. Abstract: 32. Accessed at: \u3008http:\/\/www.phaonlineuniv.org\/ResourceLibrary\/Resource.cfm?ItemNumber=3932\u3009. (Accessed 26 November 2016)."},{"key":"10.1016\/j.ejphar.2018.02.017_bib36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.02.017_bib37","doi-asserted-by":"crossref","first-page":"L1013","DOI":"10.1152\/ajplung.00217.2009","article-title":"Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure","volume":"297","author":"Stenmark","year":"2009","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2018.02.017_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12026-014-8492-5","article-title":"Leukotrienes in pulmonary arterial hypertension","volume":"58","author":"Tian","year":"2014","journal-title":"Immunol. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.02.017_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0148657","article-title":"Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension","volume":"11","author":"West","year":"2016","journal-title":"PLOSOne"},{"issue":"38","key":"10.1016\/j.ejphar.2018.02.017_bib40","doi-asserted-by":"crossref","first-page":"63430","DOI":"10.18632\/oncotarget.18825","article-title":"Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2018.02.017_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2011.08.015","article-title":"C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats","volume":"670","author":"Zopf","year":"2011","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T09:13:47Z","timestamp":1617441227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918300967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":41,"alternative-id":["S0014299918300967"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}